Sign in

    Ian Cassel

    Research Analyst at MicroCapClub

    Ian Cassel is the founder and full-time microcap investor at MicroCapClub, specializing in small and micro-cap equities with a distinct focus on profitable growth companies across diverse industries such as mining, medtech, and real estate. He has personally invested in companies like Idaho Strategic Resources (IDR) and Cogstate, and his portfolio—emphasizing quality management teams and deep due diligence—has outperformed broader market indices, with MicroCapClub’s profitable index delivering annual returns of approximately 44.8% in 2024. Beginning his career as a self-taught investor in his teens, Cassel established MicroCapClub to foster idea generation and networking among serious microcap investors, and he has authored two books on the subject. While Ian Cassel is not a registered financial advisor and does not hold formal securities licenses or FINRA registration, his influence in the micro-cap domain is reflected by the trust CEOs place in him and his reputation for integrity-driven minority investments.

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership • Q1 2025

    Question

    Ian Cassel of MicroCapClub inquired about the profitability of the retail cheese business, the velocity of new product additions to the company's catalog, and potential growth avenues in both the cheese retail and airline segments.

    Answer

    CEO Bill Bennett explained that the retail cheese business can achieve profitability at its current scale through ongoing operational efficiencies, such as reduced labor and shipping costs, which have not yet fully impacted financials. Regarding catalog growth, Bennett noted the current pace of 13 new SKUs per week is constrained by legacy systems, but a new AI-driven platform is in development to dramatically accelerate vendor onboarding from months to a fraction of that time. For future growth, he identified adjacent categories like cured meats and olives as natural extensions for the retail cheese business, while also highlighting opportunities in fresh seafood and beef, cautioning that B2B sales cycles are long.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership • Q1 2025

    Question

    Ian Cassel asked about the profitability of the cheese retail business at its current scale, the velocity of new product additions to the catalog, and the potential for future growth in cheese, airlines, and other adjacent categories.

    Answer

    CEO Bill Bennett stated that the company believes the cheese business can achieve profitability at its current scale, citing ongoing cost improvements and operational efficiencies. He noted that the new AI-driven catalog management platform is still in development, so the pace of new SKU additions has not yet accelerated. For future growth, Mr. Bennett highlighted adjacent categories like cured meats and olives as natural extensions, as well as potential opportunities in fresh seafood and beef, while cautioning that the B2B sales cycle is long.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership • Q1 2025

    Question

    Ian Cassel of MicroCapClub asked about the profitability path for the new cheese retail business, the current and targeted velocity for adding new products to the company's catalog, and the growth potential in cheese retail versus airlines, including other potential product category expansions.

    Answer

    CEO Bill Bennett addressed the questions, stating that the company believes the cheese retail business can achieve profitability at its current scale due to ongoing efficiency improvements in labor and shipping. He clarified that the new AI-driven platform to accelerate catalog additions is still in development, so the current pace remains at about 13 new SKUs per week, but the new system will enable more aggressive vendor sourcing. Regarding future growth, Bennett highlighted adjacent categories like cured meats and olives as natural extensions, along with potential opportunities in fresh seafood and beef, while noting the long B2B sales cycles involved.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership • Q1 2025

    Question

    Ian Cassel of MicroCapClub posed several questions regarding the company's strategy, asking about the path to profitability for the new retail cheese business at its current scale, the timeline and expected impact of the new AI-driven platform for accelerating catalog growth, and potential expansion opportunities in both the cheese and airline segments, including adjacent product categories.

    Answer

    CEO Bill Bennett responded, confirming that management believes the retail cheese business can become profitable at its current scale due to ongoing operational and cost efficiencies. He clarified that the new AI-powered catalog management system is still in development, so the SKU addition rate remains at the prior year's pace, but he anticipates it will significantly accelerate vendor onboarding and strengthen key partnerships like US Foods once launched. Bennett also outlined future growth avenues, identifying adjacent gourmet categories like cured meats and olives, as well as potential new verticals in fresh seafood and beef, while noting the long B2B sales cycles for such initiatives.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to INNOVATIVE FOOD HOLDINGS (IVFH) leadership • Q1 2025

    Question

    Ian Cassel of MicroCapClub asked about the path to profitability for the new cheese retail business, the current versus targeted velocity of new product additions to the company's catalog, and potential growth opportunities in cheese, airlines, and adjacent categories.

    Answer

    CEO Bill Bennett explained that the cheese business can become profitable at its current scale, citing ongoing efficiency gains in labor and shipping that are not yet reflected in financials. He noted the new AI-driven platform for accelerating catalog additions is still in development, so the current SKU addition rate remains at the historical pace of about 13 per week. Bennett also highlighted growth opportunities in adjacent categories like cured meats and fresh seafood, while cautioning that B2B sales cycles are long.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to SANUWAVE Health (SNWV) leadership

    Ian Cassel's questions to SANUWAVE Health (SNWV) leadership • Q1 2025

    Question

    Ian Cassel asked for insight into how the company's sales strategy is evolving under the new Head of Sales and what is being done differently now compared to six months ago.

    Answer

    CEO Morgan Frank responded that the core strategy to engage larger customers remains, but the team is now more senior and experienced in selling at higher corporate levels. He highlighted a continued focus on nursing homes and skilled nursing facilities, along with a strong outreach into the growing mobile and home healthcare markets.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to SANUWAVE Health (SNWV) leadership • Q4 2024

    Question

    Ian Cassel from IFCM questioned SANUWAVE's plans for new confirmatory studies to validate existing data and potentially open up new applications for the UltraMIST system.

    Answer

    CEO Morgan Frank confirmed that with a stronger financial position, the company is re-engaging with Key Opinion Leaders (KOLs) and researchers. He mentioned that customers will present retrospective data at the upcoming SAWC conference, including one with a novel application. Frank highlighted a specific interest in revisiting a previously underpowered 2015 study on split-thickness donor sites, which showed promising results in reducing wound recurrence. He suggested that proving efficacy in reducing recurrence rates for conditions like diabetic foot ulcers is a key area of focus for future prospective studies, with concrete plans expected in the next couple of quarters.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to SANUWAVE Health (SNWV) leadership • Q3 2024

    Question

    Ian Cassel of IFCM asked about any current or future clinical or validation studies and whether management sees a need for them to achieve greater market penetration.

    Answer

    Executive Morgan Frank explained that while there is already significant data on UltraMIST, the company is interested in bolstering its claims with real-world data, which is increasingly important to CMS and insurers. He also mentioned the potential for manageable prospective studies that could yield beneficial data for making new claims, suggesting they are more for enhancing claims than for initial market penetration.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to Sanara MedTech (SMTI) leadership

    Ian Cassel's questions to Sanara MedTech (SMTI) leadership • Q3 2024

    Question

    Ian Cassel from MicroCapClub asked about the types of partners Sanara is seeking for its Tissue Health Plus (THP) segment and whether that segment is expected to be immediately profitable upon its commercial launch in mid-2025.

    Answer

    An executive, identified as Sam, detailed that the company is seeking both financial partners, particularly strategics who bring execution value, and execution partners like DME providers and product suppliers. He also confirmed that the THP segment will require a ramp-up period to achieve profitability and will not be immediately profitable at launch.

    Ask Fintool Equity Research AI

    Ian Cassel's questions to LGL GROUP (LGL) leadership

    Ian Cassel's questions to LGL GROUP (LGL) leadership • Q4 2019

    Question

    Ian Cassel, a private investor from MicroCapClub.com, asked about the rationale for raising capital given the company's strong balance sheet and also requested commentary on the decline in bookings for two consecutive quarters.

    Answer

    Chairman Marc Gabelli explained that the capital was raised to position the company for strategic growth, including potential acquisitions in the defense sector where market corrections may create opportunities. He also noted it helps broaden the institutional investor base. Regarding bookings, MtronPTI President Bill Drafts clarified that they are inherently 'lumpy' due to large, long-lead-time blanket orders from defense customers. He stated that a significant Q4 order was deferred but is currently being renegotiated, and that such fluctuations are normal. Bill Drafts also highlighted positive traction with new products for the Satcom market.

    Ask Fintool Equity Research AI